EUCTR2010-020499-50-GB进行中（未招募）1 期
Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting monoclonal antibody.An investigator-led, industry supported, multicentre, open-label, single treatment arm, prospective clinical trial. - Effects of B cell depletion on bone turnover in rheumatoid arthritis.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Mimimum age 18 years.
- •2.Diagnosis of rheumatoid arthritis according to ACR classification criteria.
- •3.Eligibility for treatment with rituximab according to NICE-guidelines
- •4.First treatment course of rituximab within 6 weeks after screening
- •5.Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Use of bisphosphonates
- •2.Previous B-cell depleting therapy
- •3.Poor compliance of the patient as assessed by the referring physicians.
研究者
相似试验
已完成
不适用
Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting antibodyRheumatoid arthritisISRCTN82317088South Tees Hospitals NHS Foundation Trust (UK)46
已完成
不适用
Effect on bone turnover and Bone Mineral Density (BMD) of low dose oral silicon as an adjunct to calcium/vitamin D3 in a randomised, placebo-controlled trialISRCTN57103074Bio Minerals N.V. (Belgium)184
招募中
Unknown
A prospective study of bone mineral density changes in patients during perioperative chemotherapy for breast cancerBreast cancerJPRN-UMIN000053265Hyogo Prefectural Harima Himeji General Medical Center50
已完成
3 期
Bone density changes before and after administration of danozoomabIRCT20210803052067N1Artesh University of Medical Sciences202
招募中
不适用
Changes in bone mineral density and serum calcium levels after romosozumab treatmet in postmenopausal osteoporosis patients:About short-term results at 6 monthsJPRN-jRCT1040190111Kobayakawa Tomonori60